Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€58.93

€58.93

-40.900%
-40.72
-40.900%
€121.92
 
26.07.24 / Tradegate WKN: A0D9T1 / Symbol: DXCM / Name: DexCom / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Dexcom Inc. Stock

Dexcom Inc. took a tumble today and lost -€40.720 (-40.900%).
The stock is an absolute favorite of our community with 25 Buy predictions and no Sell predictions.
With a target price of 121 € there is potential for a 105.33% increase which would mean more than doubling the current price of 58.93 € for Dexcom Inc..
Our community identified positive and negative aspects for Dexcom Inc. stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Dexcom Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.

Pros and Cons of Dexcom Inc. in the next few years

Pros
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Dexcom Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Dexcom Inc. -40.900% -42.586% -44.563% -49.983% -47.365% -38.502% 72.587%
Zimmer Holdings -0.690% 0.443% 0.990% -19.653% -7.273% -24.945% -13.880%
Dentsply Sirona Inc. 0.080% 0.371% 3.268% -33.306% -24.394% -54.861% -51.447%
Teleflex Inc. -0.970% 2.513% 9.091% -12.069% -8.108% -38.554% -35.310%

Comments

Prediction Buy
Perf. (%) 0.00%
Target price 110.496
Change
Ends at 26.07.25

DexCom, Inc. (NASDAQ: DXCM) had its price target lowered by analysts at BTIG Research from $156.00 to $120.00. They now have a "buy" rating on the stock.
Ratings data for DXCM provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 1.45%
Target price 105.835
Change
Ends at 26.07.25

DexCom, Inc. (NASDAQ: DXCM) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $150.00 to $115.00. They now have an "outperform" rating on the stock.
Ratings data for DXCM provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 1.45%
Target price 87.429
Change
Ends at 26.07.25

DexCom, Inc. (NASDAQ: DXCM) had its price target lowered by analysts at UBS Group AG from $163.00 to $95.00. They now have a "buy" rating on the stock.
Ratings data for DXCM provided by MarketBeat
Show more

News

Why DexCom Stock Is Crashing Today: https://g.foolcdn.com/editorial/images/784772/dexcom-cgm-devices-and-apps.png
Why DexCom Stock Is Crashing Today

Shares of DexCom (NASDAQ: DXCM) were crashing 39.9% lower as of 10:20 a.m. ET on Friday. The huge sell-off came after the continuous glucose monitoring (CGM) systems maker announced its

DexCom (DXCM) Q2 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
DexCom (DXCM) Q2 2024 Earnings Call Transcript

Image source: The Motley Fool.

DexCom (NASDAQ: DXCM)Q2 2024 Earnings CallJul 25, 2024, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Dexcom Reports Second Quarter 2024 Financial Results, Updates Guidance, and Announces $750 Million Share Repurchase Program: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Reports Second Quarter 2024 Financial Results, Updates Guidance, and Announces $750 Million Share Repurchase Program


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2024.



Second Quarter 2024 Financial Highlights:




  • Revenue grew 15% year-over-year to